Figure 3:The anti-huMETCAM/MUC18 antibody significantly reduced the in vitro motility (A) and invasiveness (B) of two human prostate cancer cell lines, PC-3 and DU145, and one human bladder cancer cell line, TSU-PR1, which was originally identified as a prostate cancer cell line, but not LNCaP [22].